The global Biotechnology and Life Sciences forum, BioAsia, organised by the Government of Telangana, has announced that the Genome Valley Excellence Award for the year 2021 will be presented to Bharat Biotech International for its breakthrough, pioneering research, development and commercialization of vaccines including Covaxin.
Dr Krishna M. Ella, Chairman & Managing Director, and Suchitra Ella, Joint Managing Director, Bharat Biotech International will receive the award on February 22, 2021, during the inaugural event of BioAsia 2021.
The company has also tremendously contributed to the development of vaccines including rabies vaccine, rotavirus vaccine, Japanese Encephalitis vaccine, polio vaccine and typhoid conjugate vaccines. The company owns around 145 global patents and the products developed by them are exported to over 123 countries. It has delivered more than 4 billion doses of vaccine globally including recombinant hepatitis-B vaccine, rotavirus vaccine from a naturally attenuated strain and typhoid conjugate vaccine.
Bharat Biotech was selected by the International Advisory Board of BioAsia comprising Ajit Shetty, Corporate Vice-President – Global Operations, Johnson & Johnson USA, (retd) and Chairman Emeritus, Janssen Pharmaceutica, Belgium; Makarand Jawadekar, former Director, Pfizer, USA; Robert Naismith, former Chairman, JUJAMA, US, among others, for its vision and commitment to developing the first indigenous vaccine for COVID -19 and leading the global fight against the pandemic.
Also, the Federation of Asian Biotech Associations (FABA), which is a partner organization of BioAsia has announced that the FABA Special Award will be bestowed upon Dr Balram Bhargava for his exemplary contributions to medicine and healthcare.
Dr. Balram Bhargava has been serving as the Secretary to Government of India, Department of Health Research, Ministry of Health & Family Welfare & Director-General, Indian Council of Medical Research since 2018.
Dr Bhargava has not only spearheaded the fight against COVID-19 in India but has also commenced several extraordinary marquee projects such as India-Stanford Biodesign programme, c-GMP Centre for Excellence for Stem Cell Studies, Society for Less Investigative Medicine (SLIM) and many more. He has pioneered the development of indigenous low-cost coronary stents that have benefited several thousand patients.